355 related articles for article (PubMed ID: 33414552)
21. SLC25A21 downregulation promotes KRAS-mutant colorectal cancer progression by increasing glutamine anaplerosis.
Hu SS; Han Y; Tan TY; Chen H; Gao JW; Wang L; Yang MH; Zhao L; Wang YQ; Ding YQ; Wang S
JCI Insight; 2023 Nov; 8(21):. PubMed ID: 37937641
[TBL] [Abstract][Full Text] [Related]
22. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
[TBL] [Abstract][Full Text] [Related]
23. Oncogenic KRAS creates an aspartate metabolism signature in colorectal cancer cells.
Doubleday PF; Fornelli L; Ntai I; Kelleher NL
FEBS J; 2021 Dec; 288(23):6683-6699. PubMed ID: 34227245
[TBL] [Abstract][Full Text] [Related]
24. Inflammatory T cell responses rely on amino acid transporter ASCT2 facilitation of glutamine uptake and mTORC1 kinase activation.
Nakaya M; Xiao Y; Zhou X; Chang JH; Chang M; Cheng X; Blonska M; Lin X; Sun SC
Immunity; 2014 May; 40(5):692-705. PubMed ID: 24792914
[TBL] [Abstract][Full Text] [Related]
25. Pyruvate dehydrogenase kinase 4 exhibits a novel role in the activation of mutant KRAS, regulating cell growth in lung and colorectal tumour cells.
Trinidad AG; Whalley N; Rowlinson R; Delpuech O; Dudley P; Rooney C; Critchlow SE
Oncogene; 2017 Nov; 36(44):6164-6176. PubMed ID: 28692044
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA-30b functions as a tumour suppressor in human colorectal cancer by targeting KRAS, PIK3CD and BCL2.
Liao WT; Ye YP; Zhang NJ; Li TT; Wang SY; Cui YM; Qi L; Wu P; Jiao HL; Xie YJ; Zhang C; Wang JX; Ding YQ
J Pathol; 2014 Mar; 232(4):415-27. PubMed ID: 24293274
[TBL] [Abstract][Full Text] [Related]
27. Transcriptional and metabolic rewiring of colorectal cancer cells expressing the oncogenic KRAS
Charitou T; Srihari S; Lynn MA; Jarboui MA; Fasterius E; Moldovan M; Shirasawa S; Tsunoda T; Ueffing M; Xie J; Xin J; Wang X; Proud CG; Boldt K; Al-Khalili Szigyarto C; Kolch W; Lynn DJ
Br J Cancer; 2019 Jul; 121(1):37-50. PubMed ID: 31133691
[TBL] [Abstract][Full Text] [Related]
28. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
29. Targeting glutamine transport to suppress melanoma cell growth.
Wang Q; Beaumont KA; Otte NJ; Font J; Bailey CG; van Geldermalsen M; Sharp DM; Tiffen JC; Ryan RM; Jormakka M; Haass NK; Rasko JE; Holst J
Int J Cancer; 2014 Sep; 135(5):1060-71. PubMed ID: 24531984
[TBL] [Abstract][Full Text] [Related]
30. Dual blockade of macropinocytosis and asparagine bioavailability shows synergistic anti-tumor effects on KRAS-mutant colorectal cancer.
Hanada K; Kawada K; Nishikawa G; Toda K; Maekawa H; Nishikawa Y; Masui H; Hirata W; Okamoto M; Kiyasu Y; Honma S; Ogawa R; Mizuno R; Itatani Y; Miyoshi H; Sasazuki T; Shirasawa S; Taketo MM; Obama K; Sakai Y
Cancer Lett; 2021 Dec; 522():129-141. PubMed ID: 34543685
[TBL] [Abstract][Full Text] [Related]
31. AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer.
Ye H; Liu Y; Wu K; Luo H; Cui L
Cell Commun Signal; 2020 Jul; 18(1):115. PubMed ID: 32703218
[TBL] [Abstract][Full Text] [Related]
32. Oncogenic MYC Activates a Feedforward Regulatory Loop Promoting Essential Amino Acid Metabolism and Tumorigenesis.
Yue M; Jiang J; Gao P; Liu H; Qing G
Cell Rep; 2017 Dec; 21(13):3819-3832. PubMed ID: 29281830
[TBL] [Abstract][Full Text] [Related]
33. CEMIP, a novel adaptor protein of OGT, promotes colorectal cancer metastasis through glutamine metabolic reprogramming via reciprocal regulation of β-catenin.
Hua Q; Zhang B; Xu G; Wang L; Wang H; Lin Z; Yu D; Ren J; Zhang D; Zhao L; Zhang T
Oncogene; 2021 Nov; 40(46):6443-6455. PubMed ID: 34608265
[TBL] [Abstract][Full Text] [Related]
34. Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.
Belmont PJ; Jiang P; McKee TD; Xie T; Isaacson J; Baryla NE; Roper J; Sinnamon MJ; Lee NV; Kan JL; Guicherit O; Wouters BG; O'Brien CA; Shields D; Olson P; VanArsdale T; Weinrich SL; Rejto P; Christensen JG; Fantin VR; Hung KE; Martin ES
Sci Signal; 2014 Nov; 7(351):ra107. PubMed ID: 25389372
[TBL] [Abstract][Full Text] [Related]
35. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer.
Zhu G; Pei L; Xia H; Tang Q; Bi F
Mol Cancer; 2021 Nov; 20(1):143. PubMed ID: 34742312
[TBL] [Abstract][Full Text] [Related]
36. Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer.
Ghosh S; Fan F; Powell RT; Roszik J; Park YS; Stephan C; Sebastian M; Tan L; Sorokin AV; Lorenzi PL; Kopetz S; Ellis LM; Bhattacharya R
Mol Cancer Ther; 2023 Aug; 22(8):962-975. PubMed ID: 37310170
[TBL] [Abstract][Full Text] [Related]
37. Oncogenic mutation in RAS-RAF axis leads to increased expression of GREB1, resulting in tumor proliferation in colorectal cancer.
Kochi M; Hinoi T; Niitsu H; Miguchi M; Saito Y; Sada H; Sentani K; Sakamoto N; Oue N; Tashiro H; Sotomaru Y; Yasui W; Ohdan H
Cancer Sci; 2020 Oct; 111(10):3540-3549. PubMed ID: 32629543
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA-543 suppresses colorectal cancer growth and metastasis by targeting KRAS, MTA1 and HMGA2.
Fan C; Lin Y; Mao Y; Huang Z; Liu AY; Ma H; Yu D; Maitikabili A; Xiao H; Zhang C; Liu F; Luo Q; Ouyang G
Oncotarget; 2016 Apr; 7(16):21825-39. PubMed ID: 26968810
[TBL] [Abstract][Full Text] [Related]
39. ARID1A facilitates KRAS signaling-regulated enhancer activity in an AP1-dependent manner in colorectal cancer cells.
Sen M; Wang X; Hamdan FH; Rapp J; Eggert J; Kosinsky RL; Wegwitz F; Kutschat AP; Younesi FS; Gaedcke J; Grade M; Hessmann E; Papantonis A; Strӧbel P; Johnsen SA
Clin Epigenetics; 2019 Jun; 11(1):92. PubMed ID: 31217031
[TBL] [Abstract][Full Text] [Related]
40. Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer.
Ansari RE; Craze ML; Althobiti M; Alfarsi L; Ellis IO; Rakha EA; Green AR
Br J Cancer; 2020 Jan; 122(1):94-101. PubMed ID: 31819174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
